Submit an Abstract for ACoP9

Important Deadlines

March 5, 2018 Abstract Submissions Open
May 18, 2018 Abstract Submissions Deadline
June 29, 2018 Abstract Acceptance Notifications Sent to Primary Contact Author


Submit an Abstract


Call for Abstracts!

Abstract submission to ACoP9 is now open through May 18th! The planning committee would like to invite you to submit your work and be part of the exciting science at the conference.

We are also excited to announce many opportunities this year to showcase your work. There will be poster sessions on every day of the main conference.  In addition, there will be a poster session during the full day pre-conference, entitled “Digital Health Technology, Machine Learning and Artificial Intelligence: The Future of Clinical Trials and Informative Therapeutic Decisions? ”  If you are planning to attend the pre-conference, we encourage you to consider presenting your poster during both the pre-conference and main conference poster session.   ACoP9 will offer a poster walk session during one of the main conference poster sessions to highlight and recognize significant and thought-provoking accomplishments in Mathematical and Computational Sciences (MCS). In addition, Quality and Trainee abstract awardees will have an opportunity to orally present their works at the main conference.

Abstract Considerations

All submitted abstracts will be peer reviewed. Abstracts will be reviewed on the basis of:

Relevance: Pharmacometrics has been defined as: “the science of interpreting and describing pharmacology in a quantitative fashion”, or “the science of developing and applying mathematical and statistical methods to characterize, understand and predict a drug’s pharmacokinetic, pharmacodynamic and biomarker-outcomes behavior” (Ette and Williams, 2007).

Scientific content: Abstracts are expected to be scientific in nature and contain enough information to allow for scientific review. Abstracts without results will be rejected. (Are the methods described in sufficient detail? Does the abstract contain enough concrete evidence or results to support its conclusions? Are the results, either experimental or from computer simulation, quantitatively stated, either in table or graphical format? Alternatively, for abstracts describing a process, method or software, is the algorithm well described, has it been evaluated and are results presented? If the results are preliminary, are they characterized as such? Is the abstract purely or excessively commercial or promotional in nature?) 

Background: An appropriate level of background information should be provided to allow audience and reviewers to assess the scientific impact of the results or methodologies contained in the abstract  (Is enough background provided for the reader to understand the abstract goal? Is the literature reviewed at least to some extent and in an unbiased manner? Are citations provided?)

Innovation: Except for ENCORE presentations*, abstracts are expected to contain novel and significant information by some scientific criterion (Are the results methodologically innovative or otherwise significant? Do they shed light on certain aspects of pharmacotherapy for a particular disease? Is the methodology novel? If the methodology is not novel, is the application (to a particular problem or disease area) original? For an ENCORE submission, is the content particularly relevant to the discipline of pharmacometrics and the expected meeting audience?)

Style: abstracts should be concisely and clearly written, including structure, language, and overall exposition (Is the abstract main goal sufficiently clear? Are the results well summarized? Are there imprecision of language or errors of syntax and/or grammar? Are measurement units reported?)

*The conference may accept a limited number of selected ENCORE presentations. Their content should be particularly relevant to the discipline of pharmacometrics and the expected meeting audience. For ENCORE presentations, submitters should disclose the previous presentation in the body of the abstract and on the poster using the following suggested format: “The results in this abstract have been previously presented in part at [conference name, venue and date] and published in the conference proceedings as abstract [number]”.

Abstracts that do not comply with the guidelines may be rejected so please take the time to conform your submission.

Abstract Publication

All accepted abstracts will be published in a supplemental copy of the Journal of Pharmacokinetics and Pharmacodynamics

Abstract Guidance

Authors must adhere to a standardized format to allow for publishing.  Abstracts must be uploaded as a single word document (including all elements below and any tables or figures) using Times New Roman font size 10. The word document should be named according to the following format: "". If submitting more than one abstract, please indicate the number in the file name as well, e.g. Doe_Jane1.doc and Doe_Jane2.doc.  The general format of abstracts follows that of most major scientific meetings, and is described below:

Title: Abstract Title

Authors: List of all Authors

Institutions: Affiliations for listed Authors

Objectives: A brief description of the objectives/hypothesis of the work described

Methods: A brief description of the methods used to reach the stated objectives, or to test the hypothesis.

Results: A description of the results obtained

Conclusions: Conclusions that can be reached for the stated objectives and hypotheses.

References: References used to execute the work.

The maximum word count for abstract body is 300 words, including References, but excluding Title, Authors, and Affiliations. The attached word file may contain either one figure (inserted as a single image in JPEG or TIFF format with ≥ 300 dpi) or table which must include a title. Abstracts that do not adhere to the guidelines, including word limit and Figure/Table limit or format, will not be reviewed by the Abstract Committee, so please take the time to conform your submission.

An example abstract is provided here


Questions regarding the ACoP9 Call for Abstracts can be directed to the ACoP9 Abstracts Committee Chair, Rui Zhu, at


Submit an Abstract